Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01507285
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • liraglutide — DRUG
    Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
  • placebo — DRUG
    Initial single dose followed by subsequent multiple s.c. (under the skin) doses

Study Details

This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.

Key Dates

Start date
Aug 31, 1999
Status verified
Oct 2023
Primary completion
Nov 30, 1999
Completion
Nov 30, 1999

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC 90-1170
  • Placebo Comparator: Placebo

Primary Outcome Measure

Area under the Curve

Related Studies